Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00068952 · ClinicalTrials.gov registry record · Phase 3
Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 118
- Enrollment target
NCT00068952 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 118 participants.
The verdict
NCT00068952, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 118 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and chemotherapy.
Interventions
- DRUG Temozolomide
- DRUG Edotecarin
- DRUG Carmustine (BCNU)
- DRUG Lomustine (CCNU)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2003-08 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00068952
The ClinicalTrials.gov registry entry for NCT00068952 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT00068952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00068952 about?
NCT00068952 is a clinical study titled "Study of IV Edotecarin Vs Temozolomide or Carmustine (BCNU) or Lomustine (CCNU) in Patients With Glioblastoma Multiforme". The purpose of this clinical trial is to study Edotecarin in patients with the brain tumor glioblastoma multiforme (GBM) who have progression or first recurrence following initial treatment with surgery, radiation and chemotherapy.
What is the current status of trial NCT00068952?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 118 participants. The study started on 2003-08. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00068952?
The interventions under investigation include: Temozolomide (DRUG), Edotecarin (DRUG), Carmustine (BCNU) (DRUG), Lomustine (CCNU) (DRUG).
Who is sponsoring clinical trial NCT00068952?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.